How to improve long‐term outcome after liver transplantation?

Abstract

The outcome of liver transplantation has markedly improved in the last 3 decades. Although early post‐transplantation outcomes have improved over time, this is not true of the long‐term outcome. The majority of late deaths are not related to graft dysfunction, and with the advent of new antiviral agents, recurrence of hepatitis B and hepatitis C after transplantation may no longer represent a source of graft loss and patient’s death in the long term. The complications of metabolic syndrome may represent an increasing source of morbidity and mortality after transplantation. This study discusses these modifiable factors associated with late mortality to improve the long‐term results of transplantation.

 

KEYWORDS
de novo malignancy, immunosuppression, liver transplantation, metabolic syndrome, viral hepatitis

 

About Speaker

François DURAND

France


Biography of François DURAND

Dr François Durand is head of the Hepatology Department & Liver Intensive Care Unit of Hospital Beaujon, Clichy and Professor of Hepatology at University Paris VII Diderot, Paris, France. His main topics in research and teaching have been liver transplantation, complications of end stage cirrhosis (especially in the field of intensive care) and acute liver failure. Dr François Durand is cited in 339 publications in peer review journals in Hepatology, Gastroenterology Transplantation and Intensive Care Medicine with an author h-index of 62 (source, Scopus) and 12592 citations. He has been involved in many multicenter clinical trials in the fields of immunosuppression, management of complications of cirrhosis and viral hepatitis. He has been invited speaker for academic meetings on behalf of the American Association for the Study of Liver Disease (AASLD), the European Association for the Study of the Liver (EASL), the International Liver Transplant Society (ILTS) and the European Society of Transplantation (ESOT), among others. Dr François Durand
is currently Associate Editor of the Journal of Hepatology (impact factor 10.4), member of the council of the ILTS and secretary of the International Club of Ascites. He and his colleagues have already conducted several studies and written review articles published in high quality journals on impaired renal function in cirrhosis.

View more